Poor
Partially Aligned
Patient Risk:
Low
Summary
The supplied label section lists Wegovy presentations and storage requirements but does not substantiate the claims about changing availability, Mexican sales law, non-authorized sellers, or alternative medications. The claims are unsupported by this section, but none directly contradict it.
Category Scores
Accurate Statements
Unsupported Statements
The availability of Wegovy can change over time based on supply.
Section 16 lists presentations but does not address changing availability or supply.
The availability of Wegovy can change over time based on local regulatory approvals.
Section 16 does not discuss local regulatory approvals or their effect on availability.
If Wegovy is not listed as an approved product in Mexico, pharmacies may not legally sell it as a branded medicine.
Section 16 does not address Mexican product approvals or pharmacy sales law.
Sourcing Wegovy online from non-authorized sellers carries a risk of counterfeit products.
Section 16 does not discuss online sellers or counterfeit-product risks.
Sourcing Wegovy online from non-authorized sellers carries a risk of incorrect dosing.
Section 16 lists product strengths but does not associate online or non-authorized sourcing with incorrect dosing.
Sourcing Wegovy online from non-authorized sellers carries a risk of improper storage or handling.
Section 16 specifies storage and handling requirements but does not link improper storage or handling to online or non-authorized sellers.
Other semaglutide products may be alternatives to Wegovy, depending on approval and medical appropriateness.
Section 16 does not discuss other semaglutide products as alternatives.
Other GLP-1 medications may be alternatives to Wegovy, depending on approval and medical appropriateness.
Section 16 does not discuss other GLP-1 medications as alternatives.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide dosing or administration instructions and none directly conflicts with the supplied label section. The label does not substantiate the sourcing and alternatives claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The claims about availability, Mexican sales law, online sellers, and medication alternatives are not addressed by the supplied label section.
Suggested Improvement
Distinguish claims not covered by the prescribing information from label-supported facts; cite the label only for its listed product presentations and storage requirements.